This feature highlights changes in clinical research organizations’ personnel.
AKL Research and Development appointed Michael Martin as chief financial officer. Martin has a background in investment banking and was a founding member of Anvil Partners.
Axsome Therapeutics appointed David Marek as chief commercial officer effective Aug. 31. Marek previously was vice president and general manager of the neuroscience business unit at Amgen.
Bioasis Technologies has named Caroline Dircks chief operating officer. Dircks previously served as the head of the regional research and development operations and schedule management at Bristol Meyers Squibb for 13 years.
Biolog-id has named Troy Hilsenroth chief executive officer. Hilsenroth previously served as the vice president and general manager of the medication adherence division at Omnicell.
The Cancer Research Society has named Manon Pepin as the president and chief executive officer. Pepin was most recently the vice president for communications and public relations for the Montreal Clinical Research Institute.
Complexa has named Theodore Danoff chief medical officer. Danoff previously served as the chief medical officer and the and senior vice president of clinical and medical affairs for Clarus Therapeutics.
DrugCendR announced the addition of Daniel Van Hoff as clinical advisor. Van Hoff is currently the physician-in-chief distinguished professor at the Translational Genomics Research Institute (TGen) in Phoenix.
GlaxoSmithKline has named Maya Martinez-Davis president of its U.S. pharmaceuticals division. Martinez-Davis was previously the head of EDM Soreno’s Latin America division.
GT Biopharma has named Jeffery Miller consulting chief medical officer. Miller is currently a professor of medicine at the University of Minnesota and is the deputy director of the university’s Masonic Comprehensive Cancer Center.
Lidds has named Anja Ohlsson chief finance officer. Ohlsson previously served as the chief finance officer at Allenex/CareDX and will assume her new role September 2.
Ludi has named Danielle O’Rourke chief operating officer. O’Rourke previously founded ROND Capital, a Nashville-based private equity firm, where she served as chief executive officer.
Nadia Agopyan has been appointed as the vice president of regulatory affairs at Marker Theraputics. Agopyan was most recently the global regulatory lead and director of regulatory affairs at Kite Pharma.
Millendo Therapeutics has named Ryan Zeidan chief development officer. Zeidan previously served as vice president of development at Millendo since 2018, and before that with Celgene.
Napo Pharmaceuticals a subsidiary of Jaguar Health has named Brian Sutton to the role of national business director. Sutton previously served as western regional business director for Napo and was an executive cardiovascular hospital account manager with Novartis.
Faissal Tahiri has been named international president at Nature’s Bounty. Donato was previously global commercial lead for Pfizer’s established products division.
Christopher Barys has been appointed as chief executive officer at On Target Laboratories. Barys most recently led the Image Guided Therapy group at Philips Healthcare.
Toni Rinow has been appointed as the chief executive officer at Pivot Pharma. Rinow was most recently general manager of clinical research at Jubilant Radiopharmaceuticals. Chief medical officer at Pivot, Wolfgang Renz will be promoted to regional manager of Europe in addition to continuing his role.
Provention Bio has named Sherron Kell senior vice president of clinical development. Kell previously served as the vice president at Impax Pharmaceuticals, which is now Amneal Pharmaceuticals.
Levi Garraway has been appointed as the chief medical officer at Roche. Garraway was most recently senior vice president of oncology research and development at Eli Lilly & Co.
SEngine Precision Medicine appointed Tom Neary as chief financial officer. Neary most recently was the chief financial officer at Space Venture Partners.